Evidence map›Paper›PMID 40481864›Full record

ReviewWorld journal of urology2025

Tailoring prostate cancer external beam radiotherapy for patients with lower urinary tract symptoms.

Jennifer Le Guévelou, Romain Mathieu, Arthur Peyrottes, Charles Dariane, Vedang Murthy, Luca Nicosia, Solène-Florence Jacquet-Kammerer, Thomas Zilli, Benoit Peyronnet, Cyrus Chargari and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jennifer Le GuévelouDepartment of Research Laboratoire du Traitement de l'image et du Signal, Université de Rennes, Rennes, France. Jennifer.leguevelou@gmail.com.
Romain MathieuDepartment of Urology, CHU de Rennes, Rennes, France.
Arthur PeyrottesDepartment of Urology, Hôpital Saint-Louis, AP-HP, Université de Paris, Paris, France.
Charles DarianeDepartment of Urology, Hopital Européen Georges-Pompidou, Paris, France.
Vedang MurthyDepartment of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.
Luca NicosiaAdvanced Radiation Oncology Department, Cancer Care Center, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.
Solène-Florence Jacquet-KammererDepartment of Pathology, CHU de Rennes, Rennes, France.
Thomas ZilliDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Benoit PeyronnetDepartment of Urology, CHU de Rennes, Rennes, France.
Cyrus ChargariDepartment of Radiotherapy, Hopital Pitié-Salpétrière, Paris, France.
Julien AnractDepartment of Urology, Hopital Cochin, Paris, France.
Paul SargosCentre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, Avenue Foch, La Garenne-Colombes, 92250, France.
Stéphane SupiotDepartment of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint Herblain, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis narrative review aims to examine the biological mechanisms of toxicity in patients with benign prostatic hyperplasia (BPH) receiving prostate cancer (PCa) external beam radiotherapy (RT), as well as possible strategies to prevent genitourinary (GU) toxicity following PCa RT in men with BPH, through the adaptation of both medical, surgical, and irradiation strategies.

methodsA broad literature search was performed in November 2024 in the PubMed database with the terms "prostate cancer", "prostate epithelial cells", "prostate stromal cells", "radiation therapy", "lower urinary tract symptoms", "stereotactic body radiotherapy", "transurethral resection of the prostate", "enucleation".

resultsRT affects several pathophysiological contributors to LUTS, such as urothelial dysfunction, prostatic inflammation and bladder fibrosis. While preexisting LUTS appear to be a risk factor to develop severe GU toxicity following PCa RT, the development of strategies reducing the incidental dose delivered to urinary structures appears to be particularly relevant. Urethra-sparing strategies holds the potential to reduce the onset of severe GU toxicity following PCa RT. The relationship between the highest doses delivered to the bladder and the onset of severe GU toxicity highlight the pivotal role of image-guided radiotherapy (IGRT) for PCa RT. Aggressive margin reduction from 4 mm to 2 mm demonstrated its ability to halve the risk to develop severe GU toxicity 2 years following SBRT. De-escalation in either dose or target volume represent appealing strategies, currently assessed within prospective trials. Both assessment and optimization of urinary function through medical or surgical approaches is mandatory before RT.

conclusionStrategies designed to reduce the planned and delivered dose to functional structures hold promise for the limitation of urinary toxicity after PCa RT. Further efforts should be made to adapt surgical and irradiation techniques in men with BPH, with the development of studies dedicated to this population of patients.

Indexed as

Lower Urinary Tract SymptomsProstatic NeoplasmsHumansMaleBenign prostate hyperplasiaBladder neckIntraprostatic urethraProstate cancerStereotactic body radiotherapyUrinary toxicity

Identifiers

PMID40481864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.